Telesis bio stock.

TBIO U.S.: Nasdaq Telesis Bio Inc. Watch list Set a price target alert After Hours Last Updated: Nov 6, 2023 4:43 p.m. EST Delayed quote $ 0.7900 0.02 1.95% After Hours Volume: 1 Advanced...7 Feb 2023 ... ... Stock Exchange and the Swiss Stock Exchange (SIX) by Normax Biomed Ltd. You are cautioned not to place undue reliance upon any forward ...Telesis Bio Inc (NASDAQ:TBIO) showed a performance of -61.05% in past 30-days. Number of shares sold short was 0.32 million shares which calculate 14.15 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $4.00 to the stock, which implies a rise of 90.75% to its current value.ReShape Lifesciences Inc stock has a Value Grade of B. Telesis Bio Inc stock has a Value Grade of A. Tivic Health Systems Inc stock has a Value Grade of B. Now that you have a bit more background about each of the 3 undervalued stocks in the Advanced Medical Equipment & Technology industry as well as their overall grades, it’s …Telesis Bio's stock price has surged recently, but its but its P/S still remains modest. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market ...

Oct 13, 2023 · Get Telesis Bio Inc (TBIO.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Transcript : Telesis Bio, Inc., Q1 2023 Earnings Call, May 11, 2023 May. 11: CI Telesis Bio, Inc. Appoints Eric Esser as President May. 02: CI Telesis Bio Inc. Releases Bioxp® Select Kits to Enable DNA Amplification and Scale-Up Mar. 31: CIApr 17, 2023 · Telesis Bio's stock price has surged recently, but its but its P/S still remains modest. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market ...

About Telesis Bio Telesis Bio Inc. is building biology. Creators of the BioXp® system, the world’s only fully automated gene synthesis platform, and the industry-standard Gibson Assembly® method, Telesis Bio Inc. is focused on enabling researchers with the tools they need to rapidly and securely design, code, and create synthetic DNA.

Sep 19, 2022 · Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building of ... SAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the second quarter of 2023. “We achieved important milestones this quarter toward our path to profitability by delivering revenue growth again while expanding ...Telesis Bio (TBIO) delivered earnings and revenue surprises of 12.50% and 5.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2023 financial results on Monday, November 13, 2023, after the market closes. The press release can be accessed via the Investor section of Telesis Bio ...

SAN DIEGO, April 26, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the completion of proof-of-concept demonstrations showing that its technology can be used effectively for encoding digital data in DNA sequences, and that the information that was stored could …

SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced continued expansion of the BioXp® Select Ki t product line, releasing two novel kits to enable DNA amplification and scale-up. The BioXp® Select DNA Cloning and Amplification Kit and ...

Nov 30, 2023 · View Telesis Bio Inc TBIO investment & stock information. Get the latest Telesis Bio Inc TBIO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Oct 12, 2022 · Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building of ... SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, will showcase its recently released BioXp™ 9600 system at the World of Technology & Science conference which begins tomorrow in Utrecht, Netherlands.The BioXp™ 9600 system will be showcased at …On December 22, 2021, Codex DNA, Inc. entered into a Research Collaboration and License Agreement with Pfizer Inc., pursuant to which the Company and Pfizer agreed to collaborate to develop improvements to the Company's existing proprietary BioXP™ platform including associated instruments, kits/reagents, workflows and other …Telesis Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 Nov. 13: CI Telesis Bio, Inc. Provides Earnings Guidance for 2023 Nov. 13: CI Telesis Bio, Inc. Announces Default of 2022 Term Loan Agreement Nov. 09

November 10, 2023. $0.53. 106,682. 1:1. $0.69. $0.69. $0.50. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since ...Nov 13, 2023 · Telesis Bio is a leading synthetic biology company enabling customers to rapidly, accurately and reproducibly build or “write” high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology enabled markets. A key part of our solution is our BioXp system, an end-to-end automated workstation that fits on the ... Telesis Bio Reports Third Quarter 2023 Financial Results - Telesis Bio Skip to main navigation Home Products Coronavirus RNA controls Synthetic genomes …Dec 1, 2023 · Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system, including BioXp 3250 system, BioXp 9600 system, and BioXp DBC, which are empowers ... May 11, 2023 · Telesis Bio (TBIO) delivered earnings and revenue surprises of 2.63% and 14.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced they will be showcasing their ...10 Nov 2023 ... As of November 9, 2023, Telesis Bio's shares were trading at $0.681. Over the past 52 weeks, the shares have experienced a decline of 61.71%.

28 Jun 2023 ... The securities purchase agreement provides Telesis Bio with $28 million in initial upfront funding through the private placement of redeemable ...31 May 2023 ... ... Telesis Bio through a private placement of redeemable convertible preferred stock. The private placement also includes the issuance of ...

Discover historical prices for TBIO stock on Yahoo Finance. View daily, weekly or monthly format back to when Telesis Bio, Inc. stock was issued.May 11, 2023 · Telesis Bio (TBIO) delivered earnings and revenue surprises of 2.63% and 14.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? Telesis Bio Inc. stock performance at a glance. Check Telesis Bio Inc.’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.Codex DNA Acquires Eton Bioscience -- Acquisition will allow Codex DNA to expand its commercial BioXp™ system and biofoundry service offerings, reduce raw... | June 3, 2023Telesis Bio (TBIO) delivered earnings and revenue surprises of 12.50% and 5.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?19 Dec 2022 ... Beyond Ginkgo, Amyris and Twist there's Codexis ($CDXS), Telesis Bio ($DNAY), Pacific Bio ($PACB), Oxford Nanopore ($ONT). Some of these are ...SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the commercial release of its BioXp ...About Telesis Bio Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly ® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is …

Oct 3, 2023 3:34 PM EDT | Currency in USD Overview Key Ratios Trading Information Last Close 0.98 Sector Healthcare Industry Medical Devices Investment Style Small Blend Day Range 0.95 – 1.00 Year...

Taking into account the latest results, the most recent consensus for Telesis Bio from three analysts is for revenues of US$42.2m in 2023 which, if met, would be a substantial 101% increase on its ...

Dec 1, 2023 · Telesis Bio, Inc. (NASDAQ:DNAY) issued its quarterly earnings results on Monday, November, 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.06. The firm earned $2.79 million during the quarter, compared to analyst estimates of $2.93 million. Gainers telesis bio (nasdaq:tbio) shares increased by 32.5% to $0.53 during wednesday's after-market session. Femasys shares rose 19.28% and axcella health shares rose 13.1%. Gyre therapeutics stock decreased by 8.67% and impel pharmaceuticals declined by 13.3%.SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third ...Telesis Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 Nov. 13: CI Telesis Bio, Inc. Provides Earnings Guidance for 2023 Nov. 13: CI Telesis Bio, Inc. Announces Default of 2022 Term Loan Agreement Nov. 09This month, we saw the Telesis Bio, Inc. (NASDAQ:TBIO) up an impressive 40%.But that hardly compensates for the shocking decline over the last twelve months. Specifically, the stock price nose ...Today's High Today's Low 52 Week High 52 Week Low Stock chart FL Technical Analysis Tools & Settings Open High Low Close Volume Volume remove 1DY | 5DY | 1M | 3M | …Telesis Bio Reports Third Quarter 2023 Financial Results Nov. 13: GL Telesis Bio Reports Third Quarter 2023 Financial Results Nov. 13: AQ Telesis Bio to …Medigus Ltd - ADR stock has a Value Grade of A. Telesis Bio Inc stock has a Value Grade of B. Tivic Health Systems Inc stock has a Value Grade of B. Now that you have a bit more background about each of the 3 undervalued stocks in the Advanced Medical Equipment & Technology industry as well as their overall grades, it’s time for you …Get the LIVE share price of Translate Bio(TBIO) and stock performance in one place to strengthen your trading strategy in US stocks.The latest price target for . Telesis Bio (NASDAQ: TBIO) was reported by Keybanc on August 11, 2023.The analyst firm set a price target for $0.00 expecting TBIO to fall to within 12 months (a ...Codex DNA, Inc. (NasdaqGS:DNAY) agreed to acquire Eton Bioscience, Inc. for $13.6 million on November 9, 2021. Under the terms of the deal, Codex DNA will pay approximately $13.579 million in cash for the acquisition, which will be funded with the company's existing cash on hand.

Company profile page for Telesis Bio Inc including stock price, company news, press releases, executives, board members, and contact informationSAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced continued expansion of the BioXp® Select Ki t product line, releasing two novel kits to enable DNA amplification and scale-up. The BioXp® Select DNA Cloning and Amplification Kit and ...4 days ago ... Title of each class. Trading Symbol(s). Name of each exchange on which registered ; Common Stock, $0.0001 par value per share. TBIO. Nasdaq ...Medigus Ltd - ADR stock has a Value Grade of A. Telesis Bio Inc stock has a Value Grade of B. Tivic Health Systems Inc stock has a Value Grade of B. Now that you have a bit more background about each of the 3 undervalued stocks in the Advanced Medical Equipment & Technology industry as well as their overall grades, it’s time for you …Instagram:https://instagram. barrons advisorvalue of a 1921 silver dollar coinstock quote altria group1979 d dollar coin value SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter ... natural gas stock etfspfi Overview News Telesis Bio Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-1.31 Market Cap $11.99 M 29.98 M Public Float …TBIO Telesis Bio Inc Form 8-K - Current report. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). advance auto parts inc stock Jun 14, 2021 · SAN DIEGO, Calif., June 14, 2021 (GLOBE NEWSWIRE) — Telesis Bio, Inc. (“Telesis Bio”), creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, today announced the launch of its public offering of 6.7 million shares of its common stock. The initial public offering price is ... Mar 9, 2023 · Telesis Bio. SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its ... TBIONasdaq Stock Market • delayed by 15 minutes • CURRENCY IN USD • Healthcare Equipment & Supplies. TELESIS BIO INC. (TBIO).